Page 107 - Haematologica-5

MSH6 haploinsufficiency contributes to resistance
DNA using endogenous guanine as internal standard. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;881-882:115-118.
25. Gu L, Cline-Brown B, Zhang F, Qiu L, Li GM. Mismatch repair deficiency in hema- tological malignancies with microsatellite instability. Oncogene. 2002;21(37):5758- 5764.
26. Marra G, Iaccarino I, Lettieri T, Roscilli G, Delmastro P, Jiricny J. Mismatch repair defi- ciency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci USA. 1998;95(15):8568-8573.
27. McFaline-Figueroa JL, Braun CJ, Stanciu M, et al. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. Cancer Res. 2015; 75(15):3127-3138.
28. Xie C, Sheng H, Zhang N, Li S, Wei X, Zheng X. Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. Mol Clin Oncol. 2016; 5(2):236-240.
29. Matheson EC, Hall AG. Assessment of mis- match repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. Carcinogenesis. 2003;24(1):31-38.
30. Yoshioka K, Yoshioka Y, Hsieh P. ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell. 2006;22(4):501-510.
31. Yan T, Desai AB, Jacobberger JW, Sramkoski RM, Loh T, Kinsella TJ. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine- induced cell cycle checkpoint responses. Mol Cancer Ther. 2004;3(9):1147-1157.
32. Eich M, Roos WP, Nikolova T, Kaina B. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anti- cancer drug temozolomide. Mol Cancer Ther. 2013;12(11):2529-2540.
33. Verma L, Kane MF, Brassett C, et al. Mononucleotide microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. J Med Genet. 1999;36(9):678-682.
34. Bodo S, Colas C, Buhard O, et al. Diagnosis of Constitutional Mismatch Repair- Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. Gastroenterology. 2015;149(4):1017-1029. e1013.
35. Araten DJ, Krejci O, Ditata K, et al. The rate of spontaneous mutations in human myeloid cells. Mutat Res. 2013;749(1-2):49- 57.
36. Cahill DP, Codd PJ, Batchelor TT, Curry WT, Louis DN. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin Neurosurg. 2008;55:165-171.
37. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007; 13(7):2038-2045.
38. Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology. 2010; 78(2):103-114.
39. Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006; 66(8):3987-3991.
40. Li F, Mao G, Tong D, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell. 2013;153(3):590-600.
41. Mar BG, Bullinger LB, McLean KM, et al. Mutations in epigenetic regulators includ- ing SETD2 are gained during relapse in pae-
diatric acute lymphoblastic leukaemia. Nat
Commun. 2014;5:3469.
42. Yan T, Berry SE, Desai AB, Kinsella TJ.
DNA mismatch repair (MMR) mediates 6- thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells. Clin Cancer Res. 2003;9(6):2327-2334.
43. Tidd DM, Paterson AR. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reac- tion of 6-mercaptopurine. Cancer Res. 1974;34(4):733-737.
44. Nielsen SN, Grell K, Nersting J, Frandsen TL, Hjalgrim LL, Schmiegelow K. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in child- hood acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2016; 78(5):983-994.
45. Buza N, Ziai J, Hui P. Mismatch repair defi- ciency testing in clinical practice. Expert Rev Mol Diagn. 2016;16(5):591-604.
46. Yip S, Miao J, Cahill DP, et al. MSH6 muta- tions arise in glioblastomas during temo- zolomide therapy and mediate temozolo- mide resistance. Clin Cancer Res. 2009;15(14):4622-4629.
47. Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolo- mide in malignant glioma. Clin Cancer Res. 2008;14(15):4859-4868.
48. Umar A, Risinger JI, Glaab WE, Tindall KR, Barrett JC, Kunkel TA. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics. 1998;148(4):1637-1646.
49. Ma X, Edmonson M, Yergeau D, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6:6604.
50. van Thuijl HF, Mazor T, Johnson BE, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015;129(4):597-607.
haematologica | 2018; 103(5)
839